All Online

1 - 12 of 23 results

Refine

Active filters

Diabetes
Physician attending to patient

Maximum 50 words to introduce the activity The percentage of individuals with T2D achieving A1C <7% worsened from 2015-2018. Therapeutic inertia—failure to initiate or intensify treatment in a timely manner—is largely responsible for this problem. This program will support PCPs in overcoming therapeutic inertia through timely initiation and advancement of treatment with GLP-1 RAs and review guideline updates that support use of GLP-1 RA early in the treatment paradigm.


Physician talking with female patient
0.28 CME CREDIT

Hitting Diabetes Head-on: Improving Outcomes and Reducing Therapeutic Inertia With GLP-1 Receptor Agonists: AdaptED Module 1

An Interactive Learning ExperienceThis course is hosted by an external partner. By clicking Launch Course, you will be directed off of Pri-Med.com. Upon completing the activity, you will be prompted to return to Pri-Med.com

0.25 CME/MOC
0.28 AANP | 0.28 Pharmacology

The percentage of individuals with T2D achieving A1C <7% worsened from 2015-2018. Therapeutic inertia—failure to initiate or intensify treatment in a timely manner—is largely responsible for this problem. This program will support PCPs in overcoming therapeutic inertia through timely initiation and advancement of treatment with GLP-1 RAs and review guideline updates that support use of GLP-1 RA early in the treatment paradigm. Learners will have the opportunity to evaluate their knowledge through multiple-choice and matching questions and case-based application.


Woman Swiping Sensor With Smart Phone For Glucose Measurement
0.5 CME CREDIT

Patient Scenarios: Selecting and Implementing Digital Technology in Diabetes Care

An Interactive Case Experience

0.50 CME
0.50 CE | 0.50 Pharmacology

You know that insulin therapy is an important tool in improving quality of life and health outcomes for your patients with diabetes, but are you familiar with the expanding array of diabetes technology that can play an important role in improving insulin delivery and management? Do you know how to optimally use these tools? After this activity, you’ll be able to interpret continuous glucose monitoring data to improve time-in-range, minimize hypoglycemia, and reduce postprandial glycemic excursions. Don’t miss this opportunity to learn how to incorporate diabetes technology into clinical practice to optimize insulin management, bolster patients’ confidence in self-management of their diabetes, and, ultimately, improve health outcomes.


Doctor with hand up about to speak
0.5 CME CREDIT

Updates From the 2021 EASD and ADA Annual Meetings on Dual GIP/GLP-1 RA Therapy: What You Should Know (Module 3)

An Interactive Learning Experience From ArcheMedX This course is hosted by an external partner. By clicking Launch Course, you will be directed off of Pri-Med.com. Upon completing the activity, you will be prompted to return to Pri-Med.com

0.50 CME/MOC
0.40 AANP | 0.40 Pharmacology


man checking his blood by poking his finger
0.5 CME CREDIT

The Role of GIP and GLP-1 in the Pathophysiology of T2DM and Why it Matters (Module 2)

An Interactive Learning Experience From ArcheMedX This course is hosted by an external partner. By clicking Launch Course, you will be directed off of Pri-Med.com. Upon completing the activity, you will be prompted to return to Pri-Med.com

0.50 CME/MOC
0.42 AANP | 0.42 Pharmacology


Doctor in protective shield mask talks to obese black woman
0.28 CME CREDIT

Hitting Diabetes Head-on: Improving Outcomes and Reducing Therapeutic Inertia With GLP-1 Receptor Agonists: AdaptED Module 2

An Interactive Learning Experience This course is hosted by an external partner. By clicking Launch Course, you will be directed off of Pri-Med.com. Upon completing the activity, you will be prompted to return to Pri-Med.com

0.25 CME/MOC
0.28 AANP | 0.28 Pharmacology

The percentage of individuals with T2D achieving A1C <7% worsened from 2015-2018. Therapeutic inertia—failure to initiate or intensify treatment in a timely manner—is largely responsible for this problem. This program will support PCPs in overcoming therapeutic inertia through timely initiation and advancement of treatment with GLP-1 RAs and review guideline updates that support use of GLP-1 RA early in the treatment paradigm. Learners will have the opportunity to evaluate their knowledge through multiple-choice and matching questions and case-based application.


Coffee with Chopra: Episode 1
0.5 CME CREDIT

Advances in Diabetes and Reflections on Care

Episode 1: Coffee with Chopra

0.50 CME

Join Dr. Sanjiv Chopra, hepatologist, author, speaker, and thought leader as he interviews his guest, Dr. Martin Abrahamson, endocrinologist and associate professor at Harvard Medical School as they discuss major advances in diabetes as well as the promise of stem cell treatment, diet and weight loss in patients with diabetes, and advances in continuous glucose monitoring. The pair will end their conversation discussing what they have learned from patients over the years.


A senior woman is meeting with her female doctor. The doctor is explaining how to use an insulin pen
0.25 CME CREDIT

Therapeutic Options and Shared Decision-Making

Effective Strategies for Treating Severe Hypoglycemia

0.25 CME/MOC
0.25 AANP | 0.25 Pharmacology

Take part in this interactive case scenario that will equip you to identify which patients with diabetes need prescriptions for treatment of severe hypoglycemia, describe the currently available glucagon formulations, and pick the best option for your patient.


female stepping on scale
0.5 CME CREDIT

Addressing “Diabesity”: Weight Loss as a Key Therapeutic Goal in the Management of T2DM (Module 1)

An Interactive Learning Experience From ArcheMedX This course is hosted by an external partner. By clicking Launch Course, you will be directed off of Pri-Med.com. Upon completing the activity, you will be prompted to return to Pri-Med.com

0.50 CME/MOC
0.40 AANP | 0.04 Pharmacology


Woman looking at insulin pen while doctor looks at her
1 CME CREDIT

Updates from American Diabetes Association 2021

1.00 CME/MOC
1.00 AANP | 1.00 Pharmacology

This session will cover some new data regarding treatment of type 2 diabetes: the GRADE study, SURPASS phase 3 program, the STEP program for treatment of obesity. It will also provide an update on studies using SGLT2 inhibitors and GLP 1 receptor agonists in people with type 2 diabetes and atherosclerotic cardiovascular disease or chronic kidney disease.